The findings of a non-overlapping expression of HER2 and PD-L1 biomarkers in a GA/GEJA cohort may suggest that combinatorial strategies targeting HER2 and PD-L1 might be directed to distinct tumor subclones. This evidence concerns the gene ERBB2 and neoplasm.